Search results
New study suggests there's one way to detect signs of stomach cancer years before symptoms
UNILAD· 4 days agoA new study has found promising results in regards to early detection of stomach cancer. Last year,...
Ovarian cancer drug developer's stock cut in half after it files for FDA approval - Boston Business...
The Business Journals· 9 hours agoNeedham cancer drug developer Verastem Oncology saw its stock plunge over 60% Friday morning as of...
Most younger women who want kids after breast cancer diagnoses are successful, research data shows
ABC7 New York· 1 day agoAmong younger women with breast cancer, it may be possible for many to have a baby after their...
BostonGene Immune Profiling Platform Shows Promise in Predicting Cancer Immunotherapy Benefit
GenomeWeb News· 8 hours agoBostonGene wants to further validate a blood-based, machine learning-powered immune profiling platform that has shown potential in classifying cancer patients' immune phenotypes ...
Canadian Colorectal Cancer Screening Programs Heterogeneous
Medscape· 20 hours agoCanada's colorectal cancer (CRC) screening programs, which are run at the provincial or territorial...
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
Zacks via Yahoo Finance· 1 day agoBeyond Gene Mutations Traditionally, molecular testing in thyroid cancer has concentrated on...
Harnessing the power of viruses to kill cancers
Medical Xpress· 11 hours agoPathogens—those bugs that routinely infect and sicken us, like the common cold or influenza—are being studied in labs around the world to see if they can be used safely and effectively to attack ...
New biomarker predicts success of immunotherapy in kidney cancer
Medical Xpress· 12 hours agoEvery year, roughly 1,300 people in Austria are diagnosed with kidney cancer. Thanks to immunotherapy, survival rates for metastatic kidney cancer have ...
...Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American...
FOX 23 News Albany· 14 hours agoThe CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1...
Guardant Health Colon Cancer Screening Test Backed by Majority Amidst Robust Debate in FDA Meeting
GenomeWeb News· 11 hours agoDuring the event, which highlighted the conclusions of an FDA-commissioned group tasked with evaluating Guardant Shield, a majority of panel members voted to recognize the test as safe, likely ...